Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Leyla O. Shune, Ayman Qasrawi, Gerhard C Hildebrandt, Eric J Huselton, Howard Langstein, Dennis Allin, Kaitlyn Burrows, Andrea M Baran, Jane L. Liesveld, Neil Blumberg, Brea Lipe, Andrew G Evans, Derick R Peterson, Omar Aljitawi

Blood (2024) 144 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2024-211184

Published: 2024

Journal Articles

Therapeutic Targeting of the Inflammasome to Mitigate Murine Sclerodermatous Chronic Graft Versus Host Disease

Shanid Mohiyuddin, Vasantharaja Raguraman, Nashwan Jabbour, Melissa Kesler, Jayakrishna Ambati, Senthilnathan Palaniyandi, Gerhard C Hildebrandt

Blood (2024) 144 (Supplement 1): 3394.

https://doi.org/10.1182/blood-2024-206103

Published: 2024

Journal Articles

Stabilization of HIF-1α By the Prolyl Hydroxylase Inhibitor Roxadustat Reduces Gastrointestinal Graft-Versus-Host Disease

Vasantharaja Raguraman, Shanid Mohiyuddin, Catherine Benge, Linnea Banker, Tyler Plank, Richard D Hammer, Senthilnathan Palaniyandi, Gerhard C Hildebrandt

Blood (2024) 144 (Supplement 1): 262.

https://doi.org/10.1182/blood-2024-204027

Published: 2024

Journal Articles

Complex Restrictive Lung Disease Patterns Affecting Survival and Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant: A Single-Institution Retrospective Analysis

Christopher Graham, Runhua Shi, Gerhard C. Hildebrandt

Blood (2022) 140 (Supplement 1): 7674–7675.

https://doi.org/10.1182/blood-2022-167904

Published: 2022

Journal Articles

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Blood (2022) 140 (Supplement 1): 1716–1719.

https://doi.org/10.1182/blood-2022-157326

Published: 2022

Journal Articles

Quenching the cytokine fire in the lungs

Gerhard C. Hildebrandt

Blood (2022) 139 (22): 3231–3232.

https://doi.org/10.1182/blood.2022015992

Published: 2022

Journal Articles

Adverse Prognostic Factors in Adult Secondary Hemophagocytic Lymphohistiocytosis: Results from Two Tertiary Academic Centers

Omar Abughanimeh, MD, Ayman Qasrawi, MD, James O. Armitage, MD, Julie M. Vose, MD MBA, Gerhard C. Hildebrandt, MD, Muhamed Baljevic, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137038

Published: 2020

Journal Articles

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Alison R. Sehgal, MD, John Godwin, John Pribble, Lei Wang, PhD, Jerill Thorpe, BSc, Gerhard C. Hildebrandt, MD

Blood (2019) 134 (Supplement_1): 2882.

https://doi.org/10.1182/blood-2019-127658

Published: 2019

Journal Articles

Disparities in Plasma Cell Neoplasms in Kentucky, Appalachia and Other States: A Population Based Study

Ayman Qasrawi, MD, Richard L O'Neal, MD, Maxwell M. Krem, MD PhD, Gregory Monohan, MD, Reinhold Munker, MD, Gerhard C. Hildebrandt, MD

Blood (2019) 134 (Supplement_1): 4735.

https://doi.org/10.1182/blood-2019-127687

Published: 2019

Journal Articles

Enhancing Anti-Tumor Immunity and Responses to Immune Checkpoint Blockade By Suppressing Interleukin-10 in Chronic Lymphocytic Leukemia

Jacqueline R. Rivas, PhDBS, Sara S. Alhakeem, PhD, Joseph M. Eckenrode, PhD, Yinan Zhang, PhD, James P. Collard, BS, Gerhard C. Hildebrandt, MD, Roger A. Fleischman, MD PhD, Li Chen, PhD, Jon S. Thorson, PhD, Markos Leggas, PhD, Subbarao Bondada, PhD

Blood (2019) 134 (Supplement_1): 5486.

https://doi.org/10.1182/blood-2019-127178

Published: 2019

Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 2868.

https://doi.org/10.1182/blood-2019-127566

Published: 2019

Journal Articles

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia

Mary K. McKenna, Sunil K. Noothi, Sara S. Alhakeem, Karine Z. Oben, Joseph T. Greene, Rajeswaran Mani, Kathryn L. Perry, James P. Collard, Jacqueline R. Rivas, Gerhard C. Hildebrandt, Roger A. Fleischman, Eric B. Durbin, John C. Byrd, Chi Wang, Natarajan Muthusamy, Vivek M. Rangnekar, Subbarao Bondada

Blood (2018) 131 (26): 2943–2954.

https://doi.org/10.1182/blood-2017-10-813931

Published: 2018

Includes: Supplemental data

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Neutralization of Macrophage Migration Inhibitory Factor (MIF) Reduces GVHD but Preserves GVL.

Sandra Miklos, Dipl., Biol., Gunnar Mueller, Petra Lindner, PhD, Ya-Yi Chang, MS, Ernst Holler, MD PhD, Richard Bucala, MD PhD, Gerhard C. Hildebrandt, MD

Blood (2007) 110 (11): 3234.

https://doi.org/10.1182/blood.V110.11.3234.3234

Published: 2007

Journal Articles

CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation

Sung W. Choi, Gerhard C. Hildebrandt, Krystyna M. Olkiewicz, David A. Hanauer, Meghana N. Chaudhary, Ines A. Silva, Clare E. Rogers, Daphne T. Deurloo, Jacki M. Fisher, Chen Liu, David Adams, Stephen W. Chensue, Kenneth R. Cooke

Blood (2007) 110 (9): 3447–3455.

https://doi.org/10.1182/blood-2007-05-087403

Published: 2007

Journal Articles

Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation.

Sung Won Choi, MD, Gerhard C. Hildebrandt, MD, Ines Silva, Krystyna M. Olkiewicz, Stephen W. Chensue, MD, Chen Liu, MD, Meghana Chaudhary, Jacki Fisher, Thomas E. Lane, Kenneth R. Cooke

Blood (2005) 106 (11): 3107.

https://doi.org/10.1182/blood.V106.11.3107.3107

Published: 2005

Journal Articles

Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation

Gerhard C. Hildebrandt, Krystyna M. Olkiewicz, Sung Choi, Leigh A. Corrion, Shawn G. Clouthier, Chen Liu, Jonathan S. Serody, Kenneth R. Cooke

Blood (2005) 105 (6): 2249–2257.

https://doi.org/10.1182/blood-2004-08-3320

Published: 2005

Journal Articles

CCR1 Expression on Donor Leukocytes Is Critical to the Development of Graft Versus Host Disease after Allogeneic SCT.

Gerhard C. Hildebrandt, MD, Sung Choi, MD, Krystyna M. Olkiewicz, MS, Stephen W. Chensue, MD, Chen Liu, MD, Kenneth R. Cooke, MD

Blood (2004) 104 (11): 3067.

https://doi.org/10.1182/blood.V104.11.3067.3067

Published: 2004

Journal Articles

IL-13 - Predictor of or Protector from Acute Graft Versus Host Disease?.

Gerhard C. Hildebrandt, MD, Krystyna M. Olkiewicz, MS, Sung Choi, MD, Leigh A. Corrion, BS, Chen Liu, MD, Andrew N. McKenzie, MD, Kenneth R. Cooke, MD

Blood (2004) 104 (11): 3070.

https://doi.org/10.1182/blood.V104.11.3070.3070

Published: 2004

Journal Articles

Donor-derived TNF-α regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation

Gerhard C. Hildebrandt, Krystyna M. Olkiewicz, Leigh A. Corrion, Yayi Chang, Shawn G. Clouthier, Chen Liu, Kenneth R. Cooke

Blood (2004) 104 (2): 586–593.

https://doi.org/10.1182/blood-2003-12-4259

Published: 2004

NARROW

Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Therapeutic Targeting of the Inflammasome to Mitigate Murine Sclerodermatous Chronic Graft Versus Host Disease

Stabilization of HIF-1α By the Prolyl Hydroxylase Inhibitor Roxadustat Reduces Gastrointestinal Graft-Versus-Host Disease

Complex Restrictive Lung Disease Patterns Affecting Survival and Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant: A Single-Institution Retrospective Analysis

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Quenching the cytokine fire in the lungs

Adverse Prognostic Factors in Adult Secondary Hemophagocytic Lymphohistiocytosis: Results from Two Tertiary Academic Centers

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Disparities in Plasma Cell Neoplasms in Kentucky, Appalachia and Other States: A Population Based Study

Enhancing Anti-Tumor Immunity and Responses to Immune Checkpoint Blockade By Suppressing Interleukin-10 in Chronic Lymphocytic Leukemia

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Neutralization of Macrophage Migration Inhibitory Factor (MIF) Reduces GVHD but Preserves GVL.

CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation

Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation.

Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation

CCR1 Expression on Donor Leukocytes Is Critical to the Development of Graft Versus Host Disease after Allogeneic SCT.

IL-13 - Predictor of or Protector from Acute Graft Versus Host Disease?.

Donor-derived TNF-α regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only